SCYNEXIS Reports Favorable Phase 1 Results For ADPKD Drug

SCYNEXIS Inc. completed a Phase 1 study of SCY-770, an oral AMPK activator for Autosomal Dominant Polycystic Kidney Disease. The study enrolled 25 healthy participants and found the drug well-tolerated. SCY-770 has Orphan Drug Designation and will advance to a Phase 2 trial in Q4 2026. The drug has been evaluated in 300 participants across multiple trials. The condition has one approved therapy, Jynarque, with $1.5B in 2024 U.S. sales.

SCYNEXIS reported that SCY-770 was well tolerated in a Phase 1 study, supporting dose selection. The company plans to start a Phase 2 trial for ADPKD in Q4 2026. According to the company, this is an early clinical de-risking step.

SCYNEXIS (SCYX) reported positive Phase 1 results for SCY-770, a potential first-in-class oral direct AMPK activator for ADPKD. The study showed favorable safety and tolerability, with Phase 2 initiation on track for Q4 2026. SCY-770 has Orphan Drug Designation from the FDA.

Scynexis shares rose 10% in premarket trading after securing a BARDA contract worth up to $214 million for its antifungal treatment SCY-247. The initial funding of $18.5 million will support Phase 2 trials for invasive candidiasis. The contract could span 10 years, with additional funding contingent on progress.

Scynexis (SCYX) received a $214M contract from BARDA for developing antifungal treatment SCY-247, with an initial $18.5M payment. The 10-year contract supports phase 2 trials for invasive fungal infections. SCY-247 offers advantages over existing treatments, according to the company.

Scynexis Inc (SCYX) shares rose 10% premarket after securing a $214M contract from BARDA for SCY-247, a treatment for invasive candidiasis. The deal includes $18.5M for Phase 2 trials. SCY-247 has FDA designations and positive Phase 1 data. The company expects to fund its share of costs within its existing plan. SCYX does not anticipate changes to its guidance for SCY-770 or its cash runway into 2029.